InoCardia: Contractome-AI
Funder
EIT Digital
Horizon 2020
Total value of project
£873,617
Project team
Professor Helen Maddock; Dr Jeremy Billson, InoCardia; Dr Rob Scoffin, Cresset Group; Dr Jean-Pierre Valentin, UCB
Collaborators
Contractome-AI is a collaboration between InoCardia, Cresset BioMolecules, UCB Pharma and Coventry University, supported by EIT Digital
Duration of project
October 2019 - December 2020
Project overview
Contractome-AI is a learning engine used by Pharma & Biotech Companies in early Drug Discovery to develop safer drugs. It is an intelligent, online, virtual screen for drug-induced cardiac contractility.
Project objectives
Developing pharmaceuticals that do not show heart toxicity is particularly difficult. This is due to the lack of predictive technologies suitable for early Drug Discovery stage use. Contractome-AI meets this need by linking a drug’s key chemical and biological assay data to its effect in man, and making this available as a rapid, online, virtual screen.
It is a learning engine – the more real-world assay data added, the more predictive it becomes. Contractome-AI’s combination of novel assay and computational methods improves early detection of heart contractility issues, helping avoid expensive downstream problems.
-
Impact statement
Following funding from an EIT-Digital-Horizon 2020 award InoCardia has launched an online virtual screen named ‘The Contractome-AI’. Rather than physical testing in the lab, this provides users with the ability to perform risk-assessments on drugs using computer modelling, helping assess their safety far before they reach clinical trial stages.
The Contractome-AI is an innovative new concept bringing 'Big Data' to Safety Pharmacology, dramatically improving the early drug discovery Design-Make-Test paradigm for the 21st Century.
-
Outputs
